IGF::OT::IGF TOPIC 338 PHASE I SBIR PREDICTIVE BIOMARKERS OF ADVERSE REACTIONS TO PROSTATE CANCER RADIOTHERAPY

IGF::OT::IGF 主题 338 I 期 SBIR 前列腺癌放射治疗不良反应的预测生物标志物

• 批准号: 9150853
• 负责人: ELIZABETH PETERSON ROTH
• 金额: $ 27.12万
• 依托单位: L2 DIAGNOSTICS, LLC
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-09-22 至 2016-06-21
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9150853
• 关键词: Adverse effects; Adverse reactions; Biological Assay; Biological Markers; Cancer Patient; Clinical; Goals; Injury; Late Effects; Malignant neoplasm of prostate; Morbidity - disease rate; Performance; Phase; Radiation Tolerance; Radiation therapy; Risk; Single Nucleotide Polymorphism; Small Business Innovation Research Grant; base; cancer radiation therapy; cohort; cost; design; novel; rectal; urinary

The overall objective of this project is to identify novel biomarkers of radio-sensitivity that will identify subsets of prostate cancer patients for which radiotherapy should be contraindicated. These novel biomarkers will subsequently be packaged in a robust, validated, sensitive and specific single nucleotide polymorphism (SNP)-based assay practical for use in the clinical setting. This assay will be capable of predicting the risk of developing adverse effects – principally urinary morbidity and rectal injury – resulting from radiotherapy treatment of prostate cancer. Through previous studies we have identified SNPs in multiple cohorts that are strongly associated with adverse effects resulting from radiotherapy. The goal of the current project is to validate these SNPs and discover new SNPs using multiple, independent cohorts and to initiate design of a multiplex assay to detect predictive SNPs.

该项目的总体目标是确定新的放射敏感性生物标志物，以确定放射治疗禁忌的前列腺癌患者亚群。 这些新的生物标志物随后将被包装在一个强大的，经过验证的，敏感的和特异性的单核苷酸多态性（SNP）为基础的分析实际用于临床环境。该测定将能够预测前列腺癌放疗引起的不良反应（主要是泌尿系统发病率和直肠损伤）的风险。 通过先前的研究，我们已经在多个队列中确定了与放疗引起的不良反应密切相关的SNP。 目前项目的目标是验证这些SNP，并使用多个独立的队列发现新的SNP，并开始设计一种多重检测方法来检测预测性SNP。